window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 30, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Mental health

  • Clinical Development,Clinical Trials,Mental health,Neurosciences,Pharmaceuticals and therapeutics

    Alto starts Phase 2b ALTO-207 trial in treatment-resistant depression

    Alto Neuroscience has started a Phase 2b trial of ALTO-207 [...]

    April 22, 2026
  • Clinical Development,Clinical Trials,Digital Health,Funding,Mental health,Neurosciences,Pharmaceuticals and therapeutics

    Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy

    Click Therapeutics has secured a $50M Series D investment from [...]

    April 10, 2026
  • Central Nervous System,Mental health,Neurosciences,Research & Development

    Strategies to extend ketamine antidepressant effects identified in new study

    Researchers have identified a molecular target that could extend the [...]

    March 31, 2026
  • Artificial Intelligence,Digital Health,Mental health,Neurosciences,Research & Development

    Bullfrog AI signs commercial agreement with top 5 global pharma company to identify novel target in major depressive disorder

    BullFrog AI Holdings has entered a commercial agreement with a [...]

    March 30, 2026
  • Clinical studies,Digital Health,Global health,Mental health,Neurosciences

    Young adults in US, UK and Australia hit hardest by global mental health decline

    Young adults in wealthy countries are four times more likely [...]

    February 25, 2026
  • Clinical Trials,FDA,Mental health,Neurosciences,Pharmaceuticals and therapeutics

    Compass Pathways reports positive second Phase 3 trial for COMP360 in treatment-resistant depression

    Compass Pathways has reported that its second pivotal Phase 3 [...]

    February 18, 2026
  • Clinical Development,Clinical Trials,European biotech,Mental health,Neurosciences,Research & Development

    FundaMental Pharma to present FMP374 preclinical data in treatment-resistant depression at Bio-Neuroscience Conference

    FundaMental Pharma GmbH will present new preclinical data on its [...]

    February 17, 2026
  • Central Nervous System,Clinical Development,Clinical studies,Mental health,Neurosciences,Pharmaceuticals and therapeutics

    Newron publishes data showing clinically meaningful benefits of evenamide in treatment-resistant schizophrenia

    Newron Pharmaceuticals has published peer-reviewed clinical data demonstrating that evenamide, [...]

    February 5, 2026
  • Digital Health,Funding,Global health,Mental health,Patient Centricity

    Wellcome awards £5.3m grant to Wysa for adolescent mental health study in India

    Wellcome has awarded £5.3m in funding to digital mental health [...]

    February 3, 2026
  • Digital Health,Healthcare leadership,Medical devices,Mental health,Regulatory Affairs

    Mental health systems strain as demand and funding shifts drive push for multimodal care

    Mental health systems in the US and UK have entered [...]

    January 29, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ARTCLINE completes enrolment in septic shock trial for ARTICE therapy
    Categories: Biotech, Cell & Gene Therapy, Clinical Development, Clinical Trials, Infectious Diseases, Pharmaceuticals and therapeutics
  • SGD Pharma highlights GLP-1 demand, supply chain pressure and sustainability focus at DCAT Week
    Categories: CDMOs & Manufacturing, Healthcare leadership, Market Access & Commercialization, Pharmaceuticals and therapeutics, Supply Chain & Logistics
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top